Genelux Corp
GNLX
Company Profile
Business description
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
Contact
2625 Townsgate Road
Suite 230
Westlake VillageCA91361
USAT: +1 805 267-9889
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
24
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,828.70 | 2.30 | 0.03% |
| CAC 40 | 7,766.71 | 43.24 | 0.56% |
| DAX 40 | 24,206.91 | 133.24 | 0.55% |
| Dow JONES (US) | 44,335.55 | 70.81 | -0.16% |
| FTSE 100 | 8,854.18 | 47.65 | 0.54% |
| HKSE | 24,148.07 | 260.24 | 1.09% |
| NASDAQ | 20,466.20 | 53.68 | 0.26% |
| Nikkei 225 | 39,688.81 | 101.13 | 0.26% |
| NZX 50 Index | 12,859.02 | 94.07 | 0.74% |
| S&P 500 | 6,237.98 | 8.00 | 0.13% |
| S&P/ASX 200 | 8,590.70 | 1.40 | 0.02% |
| SSE Composite Index | 3,497.48 | 24.35 | 0.70% |